Loading...

NXTC NEXTCURE INC Product Launches 8-K Filing

NXTC

NXTC

NEXTCURE INC

(NXTC)

2025 8-K

Show Summary

Show Summary

Licensing Agreement

Earnings Releases

Corporate Update

Financial Results

New Treatment Study

Drug Application Filed

Financial Results

Earnings Reports

Annual Meeting Results

Retirement and Consulting A...

Financial Results Announcement

Regulation FD Disclosure

Earnings Reports

Financial Results Announcement

Amended Bylaws Approval

Earnings Reports

Earnings Reports

External Links:

NextCure, Inc. announced that the first patient has been dosed in its Phase 1 study of LNCB74, a new cancer treatment targeting B7-H4.

AI Assistant

NEXTCURE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.